Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism

Trial Profile

Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms XALIA
  • Sponsors Bayer
  • Most Recent Events

    • 12 Dec 2017 Results of pooled analysis of the XALIA and XALIA-LEA studies assessing tolerability and efficacy of rivaroxaban in patients with acute venous thromboembolism, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results of a subgroup analysis in patients with cancer (n=587), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Subgroup analysis results published in a Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top